About this item:

401 Views | 451 Downloads

Author Notes:

Correspondence: S. Arikawa, University of Bordeaux, Inserm, Bordeaux Population Health Research Center, 146 Rue Léo Saignat, 33076 Bordeaux Cedex, France (shino.arikawa@u-bordeaux.fr)

R. B., M. L. N., and N. R. initiated and set the objectives of the collaboration, defined the statistical analysis plans, and substantially contributed to the writing of the manuscript.

S. A. undertook the literature review, managed the data pooling, participated in the definition of the statistical analysis plan, performed statistical analysis, and wrote the first draft of the paper.

M. R. and P. J. substantially contributed to the statistical analysis.

G. J., J. H., T. F., G. G., L. K., R. S., V. L., S. L., R. C. B., T. D., and S. L. C. critically reviewed the manuscript and substantially contributed to the interpretation of the results.

All other coauthors reviewed the manuscript.

BAN: Charles van der Horst, Denise Jamieson; Ditrame-ANRSa: Christiane Welffens-Ekra, Philippe Msellati; Ditrame-ANRSb: Nicolas Meda, Philippe Van de Perre; Ditrame Plus: Marguerite Timité-Konan, Clarisse Bosse; Good Start: Mickey Chopra, Debra Jackson, Vundli Ramokolo, Ameena Goga; HIVIGLOB: J. Brooks Jackson, Laura A. Guay, Philippa Musoke, Mary Glenn Fowler, Michael C. Mubiru; PEP: Mike Urban (University of Stellenbosch); PHPT: Marc Lallemant, principal investigator of the PHPT clinical trials, all PHPT coinvestigators, the PHPT staff who helped collect and manage the data, and Nicolas Salvadori for the preparation of the data-set of the PHPT studies. PROMOTE2: Diane Havlir, Theodore Ruel. SWEN: Amita Gupta, Jayagowri Sasty, Harjot K. Singh; ZEBS: The late Moses Sinkala (Lusaka District Health Management Team), Chipepo Kankasa (University Teaching Hospital), Donald M. Thea (Boston University), Grace M. Aldrovandi (University of California–Los Angeles).

The World Health Organization (WHO) had no role in the study design, data collection, data analysis, or interpretation of data.

The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position of WHO or the Centers for Disease Control and Prevention.

All authors: No reported conflicts of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Subjects:

Research Funding:

This work was funded by the WHO.

Keywords:

  • HIV-exposed uninfected
  • children
  • infants
  • mortality
  • Africa
  • Asia

Contribution of Maternal Antiretroviral Therapy and Breastfeeding to 24-Month Survival in Human Immunodeficiency Virus-Exposed Uninfected Children: An Individual Pooled Analysis of African and Asian Studies

Show all authors Show less authors

Tools:

Journal Title:

Clinical Infectious Diseases

Volume:

Volume 66, Number 11

Publisher:

, Pages 1668-1677

Type of Work:

Article | Final Publisher PDF

Abstract:

Background Human immunodeficiency virus (HIV)-infected pregnant women increasingly receive antiretroviral therapy (ART) to prevent mother-to-child transmission (PMTCT). Studies suggest HIV-exposed uninfected (HEU) children face higher mortality than HIV-unexposed children, but most evidence relates to the pre-ART era, breastfeeding of limited duration, and considerable maternal mortality. Maternal ART and prolonged breastfeeding while on ART may improve survival, although this has not been reliably quantified. Methods Individual data on 19 219 HEU children from 21 PMTCT trials/cohorts undertaken from 1995 to 2015 in Africa and Asia were pooled to estimate the association between 24-month mortality and maternal/infant factors, using random-effects Cox proportional hazards models. Adjusted attributable fractions of risks computed using the predict function in the R package "frailtypack" were used to estimate the relative contribution of risk factors to overall mortality. Results Cumulative incidence of death was 5.5% (95% confidence interval, 5.1-5.9) by age 24 months. Low birth weight (LBW <2500 g, adjusted hazard ratio (aHR, 2.9), no breastfeeding (aHR, 2.5), and maternal death (aHR, 11.1) were significantly associated with increased mortality. Maternal ART (aHR, 0.5) was significantly associated with lower mortality. At the population level, LBW accounted for 16.2% of 24-month mortality, never breastfeeding for 10.8%, mother not receiving ART for 45.6%, and maternal death for 4.3%; combined, these factors explained 63.6% of deaths by age 24 months. Conclusions Survival of HEU children could be substantially improved if public health practices provided all HIV-infected mothers with ART and supported optimal infant feeding and care for LBW neonates.

Copyright information:

© The Author(s) 2017. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote